logo-loader

Biocept unveils second contract for its assay services with California independent physician association

Published: 09:20 26 Mar 2020 EDT

Biocept Inc -
Michael Nall, Biocept's President and CEO, said: "We are pleased to reach an agreement with a second large California-based IPA, this one in the southern part of the state, to provide liquid biopsy services for patients diagnosed with cancer"

Biocept Inc (NASDAQ: BIOC), the cancer-focused diagnostic group, has struck a deal with a second California-based independent physician association (IPA) to provide its liquid biopsy assay services to doctors and patients in its network.

The latest deal comes after, in February this year, the San-Diego based company announced an agreement with another undisclosed independent physician association in the same US state.

As part of the tie-up, the firm revealed it will offer the association an array of cancer-detection tools such as biomarker tests as well as a liquid biopsy panel to help its physicians cater to their patients.

READ: Biocept posts sixth consecutive growth quarter thanks to increase in commercial test volume

Today, Michael Nall, Biocept's President and CEO, said: "We are pleased to reach an agreement with a second large California-based IPA, this one in the southern part of the state, to provide liquid biopsy services for patients diagnosed with cancer.

"Our offerings provide evidence-based, clinically actionable results in a timely and cost-effective manner. This approach has been resonating with IPAs, ACOs, HMOs and other value-oriented stakeholders alike, and we look forward to further expanding our reach within our home state of California."

Biocept's so-called Target Selector offering includes the choice of individual biomarker tests or a larger liquid biopsy panel, enabling physicians to select the best approach for each patient, the firm said.

Another record quarter

Earlier this month, Biocept posted another record quarter  - its sixth consecutive quarter of growth - as the company saw an increase in test volume.

The biotech firm delivered revenue of $1.8 million during the fourth quarter of 2019, an increase of 108% over the same period last year.

The gain was largely driven by commercial revenue, up 94% compared to 4Q 2018 and 11% over the previous quarter in 2019.

Contact the author at giles@proactiveinvestors.com

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

3 hours, 24 minutes ago